Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update
07 mars 2018 16h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
12 févr. 2018 08h00 HE
|
Opiant Pharmaceuticals, Inc.
Based on FDA Feedback, Opiant Intends to Pursue 505 (b)(2) Development Pathway Opiant Anticipates Submitting an NDA for this Product Candidate in 2020 SANTA MONICA, Calif., Feb. 12, 2018 (GLOBE...
Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid Overdose
08 févr. 2018 08h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants
02 janv. 2018 16h01 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN® Nasal Spray for Opioid Overdose
20 déc. 2017 08h00 HE
|
Opiant Pharmaceuticals, Inc.
Opiant Expects to Receive 90% of NARCAN Sales-Related Royalty and Milestone Payments, Going Forward SANTA MONICA, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”)...
Opiant Pharmaceuticals to Ring The Nasdaq Opening Bell on December 20, 2017
19 déc. 2017 08h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine
18 déc. 2017 08h00 HE
|
Opiant Pharmaceuticals, Inc.
Data Published Online in Journal of Medicinal Chemistry Company Evaluating Potential Clinical Program for OPNT005 SANTA MONICA, Calif., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Opiant...
Opiant Pharmaceuticals, Inc. Reports Fiscal First Quarter 2018 Financial Results
04 déc. 2017 16h05 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
13 oct. 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions,...
Opiant Pharmaceuticals and Titan Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder Treatment
02 oct. 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) and Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced a collaboration to explore...